Benitec Biopharma
BNTC
3 hedge funds and large institutions have $386K invested in Benitec Biopharma in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
12% less capital invested
Capital invested by funds: $441K → $386K (-$55K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$115K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $385K | -$115K | -278 | -21% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$2.9K | -7 | -88% |
|
BNTC Hedge Fund Activity: Q3 2016 in Review
3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2016, worth a combined $386K — down 12% from $441K a quarter earlier.
Fund positioning in BNTC was balanced in Q3 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was Sabby Management, cutting an estimated $115K.
- 3 institutional investors held Benitec Biopharma (BNTC) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $386K of Benitec Biopharma stock for Q3 2016, down 12% quarter-over-quarter.
- 0 funds opened new Benitec Biopharma positions in Q3 2016 and 0 closed out.
- The largest Benitec Biopharma seller in Q3 2016 was Sabby Management, an estimated $115K sold.
Based on aggregated 13F filings for Q3 2016.